TY - JOUR
T1 - Complementemia in pregnancies with antiphospholipid syndrome
AU - Tabacco, S.
AU - Giannini, A.
AU - Garufi, C.
AU - Botta, Angela
AU - Salvi, Silvia
AU - Del Sordo, G.
AU - Benedetti Panici, P.
AU - Lanzone, Antonio
AU - De Carolis, Sara
PY - 2019
Y1 - 2019
N2 - Prognosis of pregnancies in women with antiphospholipid syndrome has dramatically improved over the past two decades using conventional treatment with low molecular weight heparin and low-dose aspirin. However, despite this regimen, 10–15% of antiphospholipid syndrome patients experience pregnancy losses. Several studies have been performed in order to identify risk factors predictive of complications. Thrombosis has been generally accepted as the key pathogenetic mechanism underlying pregnancy morbidity. However, the thrombogenic state alone is not able to explain all the different mechanisms leading to pregnancy failure. In fact, emerging evidence shows that complement pathway could play an important role in mediating clinical events in antiphospholipid syndrome. However, the exact mechanism through which complement mediates antiphospholipid syndrome complications remains unknown. Low complement levels (C3 and C4) are associated with poor pregnancy outcome in women with antiphospholipid syndrome in different studies. Hypocomplementemia could be indicated as an early predictor of adverse pregnancy outcome, available at the beginning of pregnancy for starting, if necessary, additional treatment to conventional therapy. However, future studies need to better understand the impact of low complement level on antiphospholipid syndrome pregnancy outcome.
AB - Prognosis of pregnancies in women with antiphospholipid syndrome has dramatically improved over the past two decades using conventional treatment with low molecular weight heparin and low-dose aspirin. However, despite this regimen, 10–15% of antiphospholipid syndrome patients experience pregnancy losses. Several studies have been performed in order to identify risk factors predictive of complications. Thrombosis has been generally accepted as the key pathogenetic mechanism underlying pregnancy morbidity. However, the thrombogenic state alone is not able to explain all the different mechanisms leading to pregnancy failure. In fact, emerging evidence shows that complement pathway could play an important role in mediating clinical events in antiphospholipid syndrome. However, the exact mechanism through which complement mediates antiphospholipid syndrome complications remains unknown. Low complement levels (C3 and C4) are associated with poor pregnancy outcome in women with antiphospholipid syndrome in different studies. Hypocomplementemia could be indicated as an early predictor of adverse pregnancy outcome, available at the beginning of pregnancy for starting, if necessary, additional treatment to conventional therapy. However, future studies need to better understand the impact of low complement level on antiphospholipid syndrome pregnancy outcome.
KW - Anticardiolipin antibodies
KW - antiphospholipid syndrome
KW - complement
KW - complement activation
KW - lupus anticoagulant
KW - pregnancy
KW - Anticardiolipin antibodies
KW - antiphospholipid syndrome
KW - complement
KW - complement activation
KW - lupus anticoagulant
KW - pregnancy
UR - http://hdl.handle.net/10807/147287
UR - http://lup.sagepub.com/archive/
U2 - 10.1177/0961203319882507
DO - 10.1177/0961203319882507
M3 - Article
SN - 0961-2033
VL - 28
SP - 1503
EP - 1509
JO - Lupus
JF - Lupus
ER -